Low-dose lobeglitazone effective against type 2 diabetes, study finds Medha Baranwal16 Sept 2022 11:00 AM ISTSouth Korea: The addition of low-dose lobeglitazone to the combination of metformin and DPP4 inhibitor versus standard-dose lobeglitazone led to...
Expanded dulaglutide weekly doses at par with 1.5 mg dose in type 2 diabetes with CVD risk: Study Medha Baranwal14 Sept 2022 10:45 AM ISTUSA: Findings from a post-analysis of the AWARD-11 study have suggested similar favorable effects of dulaglutide 3.0 mg and 4.5 mg on several...
Foot ulceration in diabetes mellitus associated with high mortality, finds Study Dr. Kamal Kant Kohli26 Aug 2022 9:00 PM ISTCHINA: People who have diabetic foot ulcers (DFUs) die at an excessively high rate, with nearly 50% mortality within 5 years states a research study...
High Glycemic variability and fasting blood sugar increases mortality risk in diabetes patients Jacinthlyn Sylvia20 Aug 2022 10:00 AM ISTChina: A new study suggests that it is crucial to achieve normal and stable glucose levels concurrently since the presence of high glycemic...
Dual hormone or single hormone artificial pancreas- which is better in type 1 diabetes? Medha Baranwal19 July 2022 9:15 PM ISTChina: Dual-hormone artificial pancreas (DH) compared with single hormone artificial pancreas (SH) has a comparable effect on time in target in...
Cotadutide significantly reduces blood sugar and weight in diabetics with CKD: Study Medha Baranwal29 April 2022 10:45 AM ISTUK: A recent study in the journal Diabetes, Obesity and Metabolism has found that cotadutide is an effective treatment option in patients with...
Oral semaglutide greatly reduces blood sugar and weight in type 2 diabetes patients: Study Medha Baranwal23 April 2022 9:15 AM ISTUSA: Treatment with oral semaglutide in type 2 diabetes patients results in consistently greater HbA1c reduction and weight loss, and more...
Liraglutide and semaglutide reduce MACE in diabetes patients regardless of PAD status: Study Medha Baranwal21 April 2022 9:00 AM ISTDenmark: Liraglutide and semaglutide may reduce major adverse cardiovascular events (MACE) in type 2 diabetes (T2D) patients regardless of their...
Low-carbohydrate diet improves blood sugar, body weight in type 2 diabetes: Study Medha Baranwal28 Feb 2022 10:15 AM ISTDenmark: A recent study in the journal Diabetes, Obesity and Metabolism showed a beneficial effect of a non-calorie-restricted low-carbohydrate...
Imeglimin, a potential new treatment option as add-on to insulin therapy in type 2 diabetes: TIMES 3 trial Medha Baranwal15 Feb 2022 9:15 AM ISTFrance: Recent data from the TIMES-3 trial showed that imeglimin when used as an add-on agent to insulin was effective in reducing blood sugar levels...
Type 2 diabetes: Ultra rapid lispro reduces PP glucose and shows faster pharmacokinetics than Humalog Medha Baranwal23 Nov 2021 10:00 AM ISTUSA: Ultra-rapid lispro (URLi), a novel ultra-rapid mealtime insulin, showed accelerated insulin lispro absorption and greater reduction in...
Empagliflozin reduces insulin initiation in patients with diabetes and CVD: EMPA-REG OUTCOME trial Medha Baranwal25 Oct 2021 9:30 AM ISTUSA: Empagliflozin markedly and durably delays insulin initiation and substantial increases in insulin dose in patients with type 2 diabetes and...
